Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Omipalisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 20/20 | 1.00 |
| ▸ | MTOR known ✓ | P42345 | 8/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 4/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 4/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 4/20 | 1.00 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 1.00 |
| ▸ | PRKDC | P78527 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | RICTOR | Q6R327 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 1.00 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omipalisib SCHEMBL29352875 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL623194 | 1.00 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL20734873 | 0.93 | PIK3CA (0.88) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL741445 | 0.92 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16454210 | 0.91 | PIK3CA (0.83) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL23121496 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17060446 | 0.90 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL25495105 | 0.89 | PIK3CA (0.84) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1300383 | 0.89 | PIK3CA (0.86) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL21964236 | 0.89 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 306 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028938-A | Pharmaceutical combination comprising an anti-CD 37 antibody maytansinoid conjugate and a BCL2 inhibitor or PI3K inhibitor | 德彪药业国际股份公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4661908-A1 | MTOR THERAPEUTICS FOR CANCER | GMP Biotechnology Limited (HK) | 2025-12-17 | — | — | EP | claimed |
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| WO-2024167872-A1 | MTOR THERAPEUTICS FOR CANCER | GMP BIOTECHNOLOGY LIMITED (CN) | 2024-08-15 | — | — | WO | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| EP-4333822-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | Lead Discovery Center GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| CN-117159721-A | Antitumor pharmaceutical composition for combination therapy | 上海翊维康医药有限责任公司 | 2023-12-05 | — | — | CN | claimed |
| WO-2022233782-A1 | COMPOSITION COMPRISING AN INHIBITOR OF MITOCHONDRIAL TRANSCRIPTION | LEAD DISCOVERY CENTER GMBH (DE) | 2022-11-10 | — | — | WO | claimed |
| CN-122094954-A | Tricyclic quinolones and 1, 8-naphthyridin-2-one BCL6 difunctional degrading agents | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122070915-A | Use of Maxolides for the preparation of a medicament for the treatment of pulmonary fibrosis | 上海济昀生物科技有限公司 | 2026-05-22 | — | — | CN | disclosed |
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | NOVARTIS AG (CH) | 2026-05-19 | — | — | US | disclosed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122055153-A | EGFR inhibitors for treating EGFR exon 20 mutation positive lung cancer | 安塔列斯疗法股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| WO-2022040586-A2 | COMPOSITIONS AND METHODS FOR IN VIVO GENERATION OF CAR EXPRESSING CELLS | NOVARTIS AG (CH) | 2022-02-24 | — | — | WO | disclosed |
| WO-2022035997-A1 | IN VIVO ASSEMBLY OF ASGPR BINDING THERAPEUTICS | AVILAR THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| WO-2022032132-A1 | ADVANTAGEOUS THERAPIES FOR DISORDERS MEDIATED BY IKAROS OR AIOLOS | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2022019920-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | VERASTEM, INC. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3941462-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630633-B2 | Antibody molecules to PD-1 and uses thereof | CD40, CD274, ICOS | PIK3CA 264/4885MTOR 147/4885PIK3CD 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.